Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 1, 1996, Pages 47-51

  Stein, C Michael ^a   Kinirons, Mark T ^a   Pincus, Theodore ^a   Wilkinson, Grant R ^a   Wood, Alastair J J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450; DAPSONE; ERYTHROMYCIN;

ADULT; AGED; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HUMAN; ISOTOPE LABELING; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BREATH TESTS; CARBON RADIOISOTOPES; CYCLOSPORINE; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; DAPSONE; ERYTHROMYCIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PREDICTIVE VALUE OF TESTS; PROTEIN SYNTHESIS INHIBITORS;

EID: 0030060304     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90023-5     Document Type: Article

References (29)

1. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21.
2. Ged C, Rouillon JM, Pichard L, et al. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic P450IIIA induction. Br J Clin Pharmacol 1989;28:373-87.
3. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450IIIA gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. CLIN PHARMACOL THER 1988;43:630-5.
4. Watkins PW, Wrighton SA, Maurel P, et al. Identification of an inducible form of cytochrome P-450 in human liver. Proc Natl Acad Sci USA 1985;82:6310-4.
5. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 1989;36:89-96.
6. Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistamine drug terfenadine in human liver microsomes. Drug Metab Dispos 1993;21:403-9.
7. Fleming CM, Branch RA, Wilkinson GR, Guengerich FP. Human liver microsomal N-hydroxylation of dapsone by cytochrome P4503A4. Mol Pharmacol 1992; 41:975-80.
8. Yun CH, Wood M, Wood AJJ, Guengerich FP. Identification of the pharmacogenetic determinants of alfentanil metabolism - cytochrome P-4503A4: an explanation of the variable elimination clearance. Anesthesiology 1992;77:467-74.
9. Guengerich FP, Brian WR, Iwasaki M, Saria MA, Bäärhielm C, Berntsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P450IIIA4. J Med Chem 1991;34:1838-44.
10. Wang RW, Kari PH, Lu AYH, Thomas PE, Guengerich FP, Vyas KP. Biotransformation of lovastatin; IV: identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991;290:355-61.
11. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991;256:1189-94.
12. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-83.
13. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ. The erythromycin breath test as a predictor of cyclosporine blood levels. CLIN PHARMACOL THER 1990;48:120-9.
14. Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. CLIN PHARMACOL THER 1992;52:471-8.
15. May DG, Porter J, Wilkinson GR, Branch RA. Frequency distribution of dapsone N-hydroxylase - a putative probe for P4503A4 activity in a white population. CLIN PHARMACOL THER 1994;55:492-500.
16. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
17. Horsman Y, Desager JP, Harvengt C. Absence of CYP3A genetic polymorphism assessed by urinary excretion of 6β-hydroxycortisol in 102 healthy subjects on rifampicin. Pharmacol Toxicol 1992;7:258-61.
18. Watkins PB, Turgeon DK, Saenger P, et al. Comparison of urinary 6β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. CLIN PHARMACOL THER 1992;52:265-73.
19. Kinirons MT, O'Shea D, Downing TE, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. CLIN PHARMACOL THER 1993;54:621-9.
20. May DG, Porter JA, Uetrecht JP, Wilkinson GR, Branch RA. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects. CLIN PHARMACOL THER 1990;48:619-27.
21. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450: studies in rats and patients. J Clin Invest 1989;83:688-97.
22. Turgeon DK, Leichtman AB, Lown KS, et al. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. CLIN PHARMACOL THER 1994;56: 253-60.
23. Mitra AK, Thummel KE, Unadkat JD, Slattery JT. Metabolism of dapsone in human liver by cytochrome P450 2E1 [Abstract]. ISSX Proc 1994;6:248.
24. Kolars JC, Awini WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991;338:1488-90.
25. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 1987;80:1029-36.
26. Kolars JC, Schmiedin-Ren P, Schuetz JD, Fang C, Watkins PB. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
27. Kahan BD, Welsh M, Rutzky Y, et al. The ability of pretransplant test-dose pharmacokinetic profiles to reduce early adverse events after renal transplantation. Transplantation 1992;53:345-51.
28. Hunt CM, Watkins PB, Saenger P, et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. CLIN PHARMACOL THER 1992;51:18-23.
29. Krivoruk Y, Kinirons MT, Wood AJJ, Wood M. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and the erythromycin breath test. CLIN PHARMACOL THER 1994;56:608-14.